RECRUITING

Mindfulness-Based fMRI Neurofeedback for Depression

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In the United States, adolescents experience alarmingly high rates of major depression, and gold-standard treatments are only effective for approximately half of patients. Rumination may be a promising treatment target, as it is well-characterized at the neural level and contributes to depression onset, maintenance, and recurrence as well as predicts treatment non-response. Accordingly, the proposed research will investigate whether an innovative mindfulness-based real-time functional magnetic resonance imaging (fMRI) neurofeedback intervention successfully elicits change in the brain circuit underlying rumination to improve clinical outcomes among depressed adolescents.

Official Title

Targeting Adolescent Depression Symptoms Using Network-based Real-time fMRI Neurofeedback and Mindfulness Meditation (NIMH); Mindfulness-Based Real-Time fMRI Neurofeedback for Depression (IRB)

Quick Facts

Study Start:2024-04-10
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05617495

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:13 Years to 18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ages 13-18 years-old
  2. * Written informed assent/consent and parental/guardian permission for 13-17 year-olds or informed consent for 18 year-olds
  3. * Tanner puberty stage ≥3
  4. * Meets current diagnostic criteria for MDD
  5. * English fluency
  1. * Lifetime history of primary psychotic disorders, bipolar disorder, oppositional defiant disorder, conduct disorder, developmental disorder (e.g., autism), post-traumatic stress disorder, or eating disorders
  2. * Substance use disorder, moderate or severe in past 6 months
  3. * Active suicidal ideation with a specific plan
  4. * History of seizure disorder
  5. * Medical or neurological illness (e.g., severe head injury)
  6. * MRI contraindications
  7. * Current psychotropic medication use other than antidepressant medication
  8. * Intelligence quotient (IQ) \<80.

Contacts and Locations

Study Contact

Randy P Auerbach, PhD
CONTACT
646-774-5745
rpa2009@cumc.columbia.edu
Emma Wool, BA
CONTACT
emma.wool@nyspi.columbia.edu

Study Locations (Sites)

Northeastern University
Boston, Massachusetts, 02115
United States
CUIMC
New York, New York, 10032
United States

Collaborators and Investigators

Sponsor: Columbia University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-10
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2024-04-10
Study Completion Date2026-06-30

Terms related to this study

Keywords Provided by Researchers

  • Real-time fMRI Neurofeedback
  • Mindfulness
  • Rumination
  • Major Depressive Disorder

Additional Relevant MeSH Terms

  • Depression in Adolescence
  • Rumination